Gewinn- und Verlustrechnung von Global Partners LP

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

Eli Lilly's growth rate has been accelerating over the past year due to its GLP-1 drugs. The recent approval of its GLP-1 pill, Foundayo, could offer yet another catalyst.

Kailera ​Therapeutics said ‌on ​Tuesday ​its GLP-1 ⁠drug ​for patients ​with diabetes ​and ​obesity met the ‌main ⁠goal of ​two-late ​stage ⁠trials.

Nestle is looking to spice up some of its products to counter duller taste buds that can accompany GLP-1 weight-loss drugs.

Lower crude prices have reset energy-sector expectations, making GLP, NESR and IMO buy candidates for investors seeking oil-linked opportunities.

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.

VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform. Expanding BioNxt's Thin-Film Platform into GLP-1 Therapeutics BioNxt's Semaglutide ODF program is designed to evaluate a needle-free, patient-friendly thin-film delivery format for GLP-1 receptor agonists, a class of therapeutics widely used in the treatment of type 2 diabetes, obesity, weight management, and related metabolic disorders.

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.